VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT00085696
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
B-Cell Lymphoma
Follicular Lymphoma
Marginal Lymphoma
Interventions
DRUG:
VELCADE and rituximab
Sponsor
Millennium Pharmaceuticals, Inc.